(MRVI) Maravai Lifesciences - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US56600D1072
MRVI: Nucleic Acids, Antibodies, ELISA Kits, Custom Reagents
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company specializing in products and services that support the development of drug therapies, vaccines, cell and gene therapies, and diagnostics. Operating globally across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America, the company is a key player in enabling advancements in biopharmaceuticals. Maravai operates through two primary segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on manufacturing and supplying products critical to gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This includes reagents for DNA and RNA synthesis, modification, labeling, and purification, as well as messenger RNA, oligonucleotides, CleanCap capping technology, custom enzyme development, and research products for protein labeling and detection. The Biologics Safety Testing segment offers analytical products and services for biologic manufacturing process development, such as custom antibody and assay development, HCP ELISA kits, bioprocess impurity and contaminant detection kits, viral clearance prediction kits, and ancillary reagents. Maravais products address critical stages of biopharmaceutical development, from nucleic acids for diagnostic and therapeutic applications to antibody-based solutions for detecting impurities in production. The company serves biopharmaceutical firms, research institutions, and in vitro diagnostics companies. Founded in 2014 and headquartered in San Diego, California, Maravai is a trusted partner in advancing life sciences innovation.
Based on the provided data, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is currently trading at $2.04 with a 20-day average volume of 1,554,383 shares. The stock is below its 20-day SMA of $1.93 but above its 50-day SMA of $2.30, indicating short-term volatility. The 200-day SMA of $5.73 reflects a longer-term downtrend. The ATR of 0.15 suggests relatively low price movement. Fundamentally, the company has a market cap of $756.22M, a forward P/E of 370.37, and a P/S ratio of 2.92, indicating high valuation expectations despite a negative RoE of -38.17. With no historical P/E, the market is pricing in future growth. The stocks technical and fundamental data suggest a speculative investment profile, with potential upside tied to execution in its core segments and broader biopharmaceutical industry trends.
Additional Sources for MRVI Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MRVI Stock Overview
Market Cap in USD | 756m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2020-11-20 |
MRVI Stock Ratings
Growth Rating | -91.5 |
Fundamental | -49.4 |
Dividend Rating | 0.0 |
Rel. Strength | -75.7 |
Analysts | 4/5 |
Fair Price Momentum | 1.05 USD |
Fair Price DCF | - |
MRVI Dividends
No Dividends PaidMRVI Growth Ratios
Growth Correlation 3m | -90% |
Growth Correlation 12m | -90.1% |
Growth Correlation 5y | -92.1% |
CAGR 5y | -45.01% |
CAGR/Max DD 5y | -0.46 |
Sharpe Ratio 12m | -1.79 |
Alpha | -87.52 |
Beta | 1.032 |
Volatility | 75.61% |
Current Volume | 1728.7k |
Average Volume 20d | 1516.9k |
As of May 09, 2025, the stock is trading at USD 2.07 with a total of 1,728,737 shares traded.
Over the past week, the price has changed by +1.97%, over one month by +10.11%, over three months by -51.86% and over the past year by -76.66%.
Probably not. Based on ValueRay Fundamental Analyses, Maravai Lifesciences (NASDAQ:MRVI) is currently (May 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.38 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MRVI as of May 2025 is 1.05. This means that MRVI is currently overvalued and has a potential downside of -49.28%.
Maravai Lifesciences has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy MRVI.
- Strong Buy: 8
- Buy: 1
- Hold: 6
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, MRVI Maravai Lifesciences will be worth about 1.2 in May 2026. The stock is currently trading at 2.07. This means that the stock has a potential downside of -43.48%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 5.1 | 146.4% |
Analysts Target Price | 9.1 | 338.2% |
ValueRay Target Price | 1.2 | -43.5% |